Exploring Pyrazole Derivatives as Potential Anticancer Agents: A Review

ABSTRACT Cancer remains a leading cause of global mortality, requiring the development of novel chemotherapeutics. Five membered heterocyclic compounds like pyrazole and its analogues have emerged as promising anticancer agents due to their broad biological activity and structural versatility. This review report, various studies evaluating functionalized pyrazole derivatives against various cancer cell lines, including lung (A‐549, NCIH‐460), colon (HCT‐116, COLO‐205, DLD‐1, HT29), breast (MCF‐7), renal (ACHN, EGFR, CDK), and prostate (PC‐3, DU‐145). Structure‐activity relationship (SAR) analyses reveal that targeted substitutions on the pyrazole ring enhance cytotoxicity and selectivity toward cancer cells. A comprehensive in silico study of 336 pyrazole derivatives among various cancer cells highlights favorable pharmacokinetic and ADMET profiles, including high oral bioavailability, drug‐likeness, and low toxicity. These findings emphasize the value of computational pipelines in accelerating the prioritization of lead compounds for further biological validation.